In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arbutus, Roivant further existing RNA deal through formation of Genevant JV

Executive Summary

Continuing a relationship that began last year, Arbutus Biopharma Corp. and Roivant Sciences GMBH entered a new agreement in which they aim to further the efforts of their hepatitis B virus (HBV) partnership by forming an equally owned joint venture called Genevant Sciences Ltd., to develop RNA-based drugs in other therapeutic areas.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Joint Venture
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies